Verrica End Period Cash Flow vs Begin Period Cash Flow Analysis

VRCA Stock

USD 0.99 0.01 1.00%

Verrica Pharmaceuticals financial indicator trend analysis is much more than just breaking down Verrica Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Verrica Pharmaceuticals is a good investment. Please check the relationship between Verrica Pharmaceuticals End Period Cash Flow and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

End Period Cash Flow vs Begin Period Cash Flow

End Period Cash Flow vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Verrica Pharmaceuticals End Period Cash Flow account and Begin Period Cash Flow. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Verrica Pharmaceuticals' End Period Cash Flow and Begin Period Cash Flow is 0.98. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Verrica Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Verrica Pharmaceuticals' End Period Cash Flow and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Verrica Pharmaceuticals are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of End Period Cash Flow i.e., Verrica Pharmaceuticals' End Period Cash Flow and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

End Period Cash Flow

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Verrica Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Verrica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 2.30, whereas Selling General Administrative is forecasted to decline to about 17.5 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	472K	718K	836K	464.2K
Interest Income	123K	476K	2.2M	2.3M

Depreciation And Amortization Interest Income

Verrica Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Preferred Stock Total Equity	Total Current Assets	Short Term Debt	Common Stock	Common Stock Total Equity	Net Invested Capital	Net Working Capital	Property Plant And Equipment Net	Other Assets
Total Assets		0.58	0.65	0.85	0.91	-0.35	-0.72	0.7	0.73	1.0	0.49	0.47	0.89	0.66	0.78	0.64	0.93	0.86	1.0	0.48	0.88	0.8	0.99	0.87	0.7	0.09
Other Current Liab	0.58		0.39	0.28	0.43	-0.2	-0.89	0.95	0.71	0.55	0.76	0.88	0.64	0.35	0.69	0.89	0.73	0.45	0.58	0.06	0.69	0.74	0.54	0.52	0.55	-0.44
Total Current Liabilities	0.65	0.39		0.27	0.31	0.4	-0.58	0.33	0.17	0.62	0.39	0.47	0.6	0.66	0.62	0.75	0.61	0.53	0.62	0.94	0.5	0.44	0.63	0.21	0.78	0.18
Total Stockholder Equity	0.85	0.28	0.27		0.96	-0.62	-0.43	0.5	0.7	0.87	0.14	0.13	0.68	0.51	0.49	0.22	0.76	0.74	0.86	0.18	0.7	0.58	0.89	0.92	0.42	0.19
Net Tangible Assets	0.91	0.43	0.31	0.96		-0.62	-0.55	0.63	0.77	0.93	0.32	0.27	0.78	0.51	0.61	0.35	0.84	0.75	0.92	0.17	0.79	0.73	0.93	0.98	0.48	0.1
Net Debt	-0.35	-0.2	0.4	-0.62	-0.62		0.14	-0.36	-0.78	-0.38	0.0	0.0	-0.27	0.03	-0.06	0.12	-0.31	-0.29	-0.38	0.52	-0.36	-0.35	-0.37	-0.71	0.15	0.32
Retained Earnings	-0.72	-0.89	-0.58	-0.43	-0.55	0.14		-0.85	-0.66	-0.68	-0.88	-0.75	-0.88	-0.73	-0.92	-0.86	-0.9	-0.67	-0.71	-0.31	-0.88	-0.91	-0.67	-0.55	-0.85	0.33
Accounts Payable	0.7	0.95	0.33	0.5	0.63	-0.36	-0.85		0.79	0.69	0.69	0.75	0.7	0.37	0.7	0.8	0.81	0.55	0.71	0.01	0.75	0.77	0.68	0.72	0.51	-0.38
Cash	0.73	0.71	0.17	0.7	0.77	-0.78	-0.66	0.79		0.74	0.42	0.53	0.66	0.32	0.52	0.53	0.74	0.58	0.75	-0.07	0.73	0.72	0.73	0.86	0.35	-0.41
Cash And Short Term Investments	1.0	0.55	0.62	0.87	0.93	-0.38	-0.68	0.69	0.74		0.43	0.45	0.86	0.61	0.73	0.61	0.91	0.84	1.0	0.46	0.85	0.76	0.99	0.89	0.65	0.1
Common Stock Shares Outstanding	0.49	0.76	0.39	0.14	0.32	0.0	-0.88	0.69	0.42	0.43		0.64	0.79	0.57	0.89	0.7	0.68	0.55	0.48	0.14	0.78	0.87	0.39	0.35	0.71	-0.33
Non Current Liabilities Total	0.47	0.88	0.47	0.13	0.27	0.0	-0.75	0.75	0.53	0.45	0.64		0.5	0.22	0.57	0.87	0.59	0.33	0.46	0.2	0.54	0.59	0.44	0.34	0.5	-0.13
Capital Surpluse	0.89	0.64	0.6	0.68	0.78	-0.27	-0.88	0.7	0.66	0.86	0.79	0.5		0.82	0.96	0.66	0.95	0.85	0.88	0.4	0.97	0.96	0.84	0.74	0.85	-0.09
Other Current Assets	0.66	0.35	0.66	0.51	0.51	0.03	-0.73	0.37	0.32	0.61	0.57	0.22	0.82		0.82	0.49	0.79	0.67	0.63	0.59	0.75	0.7	0.63	0.38	0.94	-0.05
Other Stockholder Equity	0.78	0.69	0.62	0.49	0.61	-0.06	-0.92	0.7	0.52	0.73	0.89	0.57	0.96	0.82		0.72	0.9	0.8	0.76	0.41	0.94	0.94	0.71	0.57	0.9	-0.11
Total Liab	0.64	0.89	0.75	0.22	0.35	0.12	-0.86	0.8	0.53	0.61	0.7	0.87	0.66	0.49	0.72		0.73	0.47	0.63	0.5	0.64	0.66	0.61	0.37	0.71	-0.25
Short Long Term Debt	0.93	0.73	0.61	0.76	0.84	-0.31	-0.9	0.81	0.74	0.91	0.68	0.59	0.95	0.79	0.9	0.73		0.81	0.92	0.39	0.94	0.91	0.91	0.8	0.84	-0.09
Preferred Stock Total Equity	0.86	0.45	0.53	0.74	0.75	-0.29	-0.67	0.55	0.58	0.84	0.55	0.33	0.85	0.67	0.8	0.47	0.81		0.85	0.4	0.91	0.77	0.8	0.71	0.67	0.11
Total Current Assets	1.0	0.58	0.62	0.86	0.92	-0.38	-0.71	0.71	0.75	1.0	0.48	0.46	0.88	0.63	0.76	0.63	0.92	0.85		0.45	0.87	0.79	0.99	0.89	0.67	0.07
Short Term Debt	0.48	0.06	0.94	0.18	0.17	0.52	-0.31	0.01	-0.07	0.46	0.14	0.2	0.4	0.59	0.41	0.5	0.39	0.4	0.45		0.28	0.19	0.48	0.02	0.65	0.34
Common Stock	0.88	0.69	0.5	0.7	0.79	-0.36	-0.88	0.75	0.73	0.85	0.78	0.54	0.97	0.75	0.94	0.64	0.94	0.91	0.87	0.28		0.97	0.82	0.77	0.79	-0.11
Common Stock Total Equity	0.8	0.74	0.44	0.58	0.73	-0.35	-0.91	0.77	0.72	0.76	0.87	0.59	0.96	0.7	0.94	0.66	0.91	0.77	0.79	0.19	0.97		0.74	0.73	0.77	-0.22
Net Invested Capital	0.99	0.54	0.63	0.89	0.93	-0.37	-0.67	0.68	0.73	0.99	0.39	0.44	0.84	0.63	0.71	0.61	0.91	0.8	0.99	0.48	0.82	0.74		0.88	0.66	0.11
Net Working Capital	0.87	0.52	0.21	0.92	0.98	-0.71	-0.55	0.72	0.86	0.89	0.35	0.34	0.74	0.38	0.57	0.37	0.8	0.71	0.89	0.02	0.77	0.73	0.88		0.37	-0.02
Property Plant And Equipment Net	0.7	0.55	0.78	0.42	0.48	0.15	-0.85	0.51	0.35	0.65	0.71	0.5	0.85	0.94	0.9	0.71	0.84	0.67	0.67	0.65	0.79	0.77	0.66	0.37		-0.01
Other Assets	0.09	-0.44	0.18	0.19	0.1	0.32	0.33	-0.38	-0.41	0.1	-0.33	-0.13	-0.09	-0.05	-0.11	-0.25	-0.09	0.11	0.07	0.34	-0.11	-0.22	0.11	-0.02	-0.01

Click cells to compare fundamentals

Verrica Pharmaceuticals Account Relationship Matchups

Verrica Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	68.4M	74.2M	80.1M	44.7M	81.6M	62.0M
Other Current Liab	2.0M	2.9M	3.3M	2.4M	13.2M	13.8M
Total Current Liabilities	3.4M	39.5M	46.1M	3.5M	17.0M	15.5M
Total Stockholder Equity	65.0M	33.0M	32.6M	40.0M	19.8M	39.3M
Net Tangible Assets	65.0M	33.0M	32.6M	40.0M	46.0M	39.3M
Net Debt	(9.1M)	24.6M	27.7M	(32.7M)	(24.0M)	(25.2M)
Retained Earnings	(61.2M)	(103.9M)	(139.0M)	(163.5M)	(230.4M)	(218.9M)
Accounts Payable	1.2M	348K	845K	507K	2.5M	2.6M
Cash	9.2M	10.7M	15.8M	34.3M	69.5M	73.0M
Non Current Assets Total	3.4M	8.7M	5.8M	5.6M	4.1M	4.1M
Non Currrent Assets Other	830K	3.7M	295K	276K	452K	429.4K
Cash And Short Term Investments	62.0M	65.5M	70.4M	34.3M	69.5M	55.1M
Common Stock Shares Outstanding	24.9M	25.0M	27.0M	34.2M	45.3M	29.0M
Liabilities And Stockholders Equity	68.4M	74.2M	80.1M	44.7M	81.6M	62.0M
Non Current Liabilities Total	58K	35.3M	1.5M	1.2M	44.8M	47.1M
Capital Surpluse	126.6M	136.9M	171.6M	203.5M	234.0M	120.4M
Other Current Assets	3.0M	4.4M	7.9M	8.7M	2.5M	3.9M
Other Stockholder Equity	126.2M	136.9M	171.6M	203.5M	250.2M	128.8M
Total Liab	3.4M	41.2M	47.5M	4.7M	61.8M	64.9M
Total Current Assets	65.0M	65.5M	74.3M	39.1M	77.5M	57.9M
Net Invested Capital	65.0M	68.3M	74.3M	40.0M	62.6M	64.1M
Net Working Capital	61.6M	28.2M	28.3M	35.7M	60.5M	48.9M
Property Plant And Equipment Net	2.2M	4.9M	5.8M	5.6M	3.6M	4.1M
Other Assets	1.2M	1.6M	295K	276K	1.0	0.95
Retained Earnings Total Equity	(61.2M)	(103.9M)	(139.0M)	(163.5M)	(147.1M)	(154.5M)
Property Plant And Equipment Gross	2.2M	4.9M	5.8M	6.0M	4.8M	4.4M
Property Plant Equipment	2.2M	4.9M	3.9M	3.9M	4.5M	3.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:

How To Invest In Verrica

Details

Is Verrica Stock a good investment?

Details

What is Verrica Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.84)

Revenue Per Share

0.198

Quarterly Revenue Growth

27.445

Return On Assets

(0.71)

Return On Equity

(20.60)

The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Verrica End Period Cash Flow vs Begin Period Cash Flow Analysis

End Period Cash Flow vs Begin Period Cash Flow

End Period Cash Flow vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Begin Period Cash Flow

Verrica Pharmaceuticals fundamental ratios Correlations

Verrica Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Verrica Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Invested Capital	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Cash And Short Term Investments
Net Invested Capital	+ 0.99	Total Current Assets

Other Stockholder Equity	- 0.92	Retained Earnings
Common Stock Total Equity	- 0.91	Retained Earnings
Short Long Term Debt	- 0.9	Retained Earnings
Retained Earnings	- 0.89	Other Current Liab
Common Stock	- 0.88	Retained Earnings
Capital Surpluse	- 0.88	Retained Earnings